Zobrazeno 1 - 10 of 3 703 pro vyhledávání: '"Lieb, S."'
1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
3
Akademický článek
Automated Tomographic Assessment of Structural Defects of Freeze-Dried Pharmaceuticals.
Autor: Müller P; Institut für Multiskalensimulation, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany., Sack A; Institut für Multiskalensimulation, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany., Dümler J; Institut für Multiskalensimulation, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany., Heckel M; Institut für Multiskalensimulation, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.; IT Unit, University of Technology Nuremberg, Nuremberg, Germany., Wenzel T; Division of Pharmaceutics, Friedrich-Alexander-Universität Erlangen-Nürnberg, Freeze Drying Focus Group, Erlangen, Germany.; GILYOS GmbH, Würzburg, Germany., Siegert T; Division of Pharmaceutics, Friedrich-Alexander-Universität Erlangen-Nürnberg, Freeze Drying Focus Group, Erlangen, Germany., Schuldt-Lieb S; medac GmbH, Wedel, Germany., Gieseler H; GILYOS GmbH, Würzburg, Germany., Pöschel T; Institut für Multiskalensimulation, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany. thorsten.poeschel@fau.de.
Publikováno v: AAPS PharmSciTech [AAPS PharmSciTech] 2024 Jun 25; Vol. 25 (6), pp. 143. Date of Electronic Publication: 2024 Jun 25.
Zobrazit plný text záznamu
4
Akademický článek
Co-targeting SOS1 enhances the antitumor effects of KRAS G12C inhibitors by addressing intrinsic and acquired resistance.
Autor: Thatikonda V; Boehringer Ingelheim RCV, Vienna, Austria. vthatikonda@exscientia.co.uk.; Exscientia, Vienna, Austria. vthatikonda@exscientia.co.uk., Lyu H; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jurado S; Boehringer Ingelheim RCV, Vienna, Austria., Kostyrko K; Boehringer Ingelheim RCV, Vienna, Austria., Bristow CA; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Albrecht C; Boehringer Ingelheim RCV, Vienna, Austria., Alpar D; Boehringer Ingelheim RCV, Vienna, Austria., Arnhof H; Boehringer Ingelheim RCV, Vienna, Austria., Bergner O; Boehringer Ingelheim RCV, Vienna, Austria., Bosch K; Boehringer Ingelheim RCV, Vienna, Austria., Feng N; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gao S; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gerlach D; Boehringer Ingelheim RCV, Vienna, Austria., Gmachl M; Boehringer Ingelheim RCV, Vienna, Austria., Hinkel M; Boehringer Ingelheim RCV, Vienna, Austria., Lieb S; Boehringer Ingelheim RCV, Vienna, Austria., Jeschko A; Boehringer Ingelheim RCV, Vienna, Austria., Machado AA; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Madensky T; Boehringer Ingelheim RCV, Vienna, Austria., Marszalek ED; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mahendra M; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Melo-Zainzinger G; Boehringer Ingelheim RCV, Vienna, Austria., Molkentine JM; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jaeger PA; Boehringer Ingelheim RCV, Vienna, Austria., Peng DH; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Schenk RL; Boehringer Ingelheim RCV, Vienna, Austria., Sorokin A; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Strauss S; Boehringer Ingelheim RCV, Vienna, Austria., Trapani F; Boehringer Ingelheim RCV, Vienna, Austria., Kopetz S; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Vellano CP; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Petronczki M; Boehringer Ingelheim RCV, Vienna, Austria., Kraut N; Boehringer Ingelheim RCV, Vienna, Austria., Heffernan TP; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Marszalek JR; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Pearson M; Boehringer Ingelheim RCV, Vienna, Austria., Waizenegger IC; Boehringer Ingelheim RCV, Vienna, Austria., Hofmann MH; Boehringer Ingelheim RCV, Vienna, Austria. marco.hofmann@boehringer-ingelheim.com.
Publikováno v: Nature cancer [Nat Cancer] 2024 Sep; Vol. 5 (9), pp. 1352-1370. Date of Electronic Publication: 2024 Aug 05.
Zobrazit plný text záznamu
7
Report
Numerical Models for the Diffuse Ionized Gas in Galaxies. I. Synthetic spectra of thermally excited gas with turbulent magnetic reconnection as energy source
Autor: Hoffmann, T. L., Lieb, S., Pauldrach, A. W. A., Lesch, H., Hultzsch, P. J. N., Birk, G. T.
Aims: The aim of this work is to verify whether turbulent magnetic reconnection can provide the additional energy input required to explain the up to now only poorly understood ionization mechanism of the diffuse ionized gas (DIG) in galaxies and its
Externí odkaz: http://arxiv.org/abs/1206.0394
Zobrazit plný text záznamu
8
Akademický článek
[Nonpharmacological treatment measures, rehabilitation services and membership in patient support groups in axial spondylarthritis (The ATTENTUS axSpA study)].
Autor: Meyer-Olson D; Klinik für Rheumatologie und Immunologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland. meyer-olson.dirk@mh-hannover.de.; Rheumatologie und Immunologie, m&i Fachklinik Bad Pyrmont/MVZ Weserbergland, Bad Pyrmont, Deutschland. meyer-olson.dirk@mh-hannover.de., Hoeper K; Klinik für Rheumatologie und Immunologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland.; Regionales Kooperatives Rheumazentrum Niedersachsen e. V., Hannover, Deutschland., Hammel L; Deutsche Vereinigung Morbus Bechterew e. V., Schweinfurt, Deutschland., Lieb S; Novartis Pharma GmbH, Nürnberg, Deutschland., Haehle A; Novartis Pharma GmbH, Nürnberg, Deutschland., Kiltz U; Rheumazentrum Ruhrgebiet, Herne, Deutschland.; Ruhr Universität, Bochum, Deutschland.
Publikováno v: Zeitschrift fur Rheumatologie [Z Rheumatol] 2024 Aug; Vol. 83 (6), pp. 500-509. Date of Electronic Publication: 2023 Sep 19.
Zobrazit plný text záznamu
9
Akademický článek
Efficacy and NSAID-sparing effect of secukinumab 150 mg in ankylosing spondylitis: results from phase IV ASTRUM study.
Autor: Kiltz U; Rheumazentrum Ruhrgebiet, Claudiusstr 45, Bochum 44649, Herne, Germany.; Ruhr-Universität Bochum, Bochum, Germany and Rheumazentrum Ruhrgebiet, Herne, Germany., Baraliakos X; Ruhr-Universität Bochum, Bochum, Germany and Rheumazentrum Ruhrgebiet, Herne, Germany., Brandt-Jürgens J; Rheumatologische Schwerpunktpraxis, Berlin, Germany., Wagner U; Rheumatology Section, Division of Rheumatology, Department of Internal Medicine, University Hospital Leipzig AöR, Clinic and Polyclinic for Gastroenterology and Rheumatology, Leipzig, Germany., Lieb S; Medical Franchise Immunology, Novartis Pharma GmbH, Nürnberg, Germany., Sieder C; Biostatistics Department, Novartis Pharma GmbH, Nürnberg, Germany., Mann C; Medical Franchise Immunology, Novartis Pharma GmbH, Nürnberg, Germany., Braun J; Rheumatologisches Versorgungszentrum RVZ Steglitz Berlin, Germany.
Publikováno v: Therapeutic advances in musculoskeletal disease [Ther Adv Musculoskelet Dis] 2024 Jun 05; Vol. 16, pp. 1759720X241255486. Date of Electronic Publication: 2024 Jun 05 (Print Publication: 2024).
Zobrazit plný text záznamu
10
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje